Literature DB >> 26632188

Characterization of Motor Neuron Prostaglandin E2 EP3 Receptor Isoform in a Mouse Model of Amyotrophic Lateral Sclerosis.

Yasuhiro Kosuge1, Hiroko Miyagishi, Takashi Shinomiya, Kenta Nishiyama, Satomi Suzuki, Nobuhiro Osada, Kumiko Ishige, Migiwa Okubo, Mitsuru Kawaguchi, Yoshihisa Ito.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with adult onset, characterized by progressive loss of motor neurons. Prostaglandin E2 (PGE2), a lipid mediator, exerts its biological functions by binding to four subtypes of E-prostanoid (EP1-4). Among them, EP3 has been shown to have multiple isoforms, EP3α, EP3β, and EP3γ, produced by alternative splicing. Since PGE2 has been shown to have important pathophysiological roles in ALS, experiments were performed to identify EP3 receptor isoform(s) in spinal motor neurons of wild-type (WT) and ALS model (G93A) mice. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of adult mice demonstrated expression of EP3α and EP3γ mRNAs in the lumbar spinal cord, whereas EP3β mRNA was barely detectable. Laser capture microdissection was used to dissect out motor neurons from frozen samples of lumbar spinal cord in these mice for analysis by real-time PCR. We found that expression of EP3γ mRNA was predominant in these neurons, whereas EP3α and EP3β mRNAs were undetectable. At the early symptomatic stage, the mRNA expression profiles of these splice isoforms in G93A motor neurons were comparable to those in neurons from WT mice. These results suggest that the PGE2-to-EP3 signaling pathway is mediated mainly by the EP3γ isoform in the motor neurons of mice, and that modulation of the EP3γ isoform in motor neurons may be a promising new therapeutic approach for ALS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26632188     DOI: 10.1248/bpb.b15-00418

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

1.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

2.  Prostaglandin E2 promotes human CD34+ cells homing through EP2 and EP4 in vitro.

Authors:  Yaqun Wang; Shuping Lai; Jing Tang; Chun Feng; Fangjie Liu; Chang Su; Waiyi Zou; Huizhen Chen; Duorong Xu
Journal:  Mol Med Rep       Date:  2017-05-30       Impact factor: 2.952

3.  Alterations in the stomatognathic system due to amyotrophic lateral sclerosis.

Authors:  Lígia Maria Napolitano Gonçalves; Marcelo Palinkas; Jaime Eduardo Cecilio Hallak; Wilson Marques Júnior; Paulo Batista de Vasconcelos; Nicolly Parente Ribeiro Frota; Isabela Hallak Regalo; Selma Siéssere; Simone Cecilio Hallak Regalo
Journal:  J Appl Oral Sci       Date:  2018-06-11       Impact factor: 2.698

4.  Generation of Cellular Reactive Oxygen Species by Activation of the EP2 Receptor Contributes to Prostaglandin E2-Induced Cytotoxicity in Motor Neuron-Like NSC-34 Cells.

Authors:  Yasuhiro Kosuge; Hiroshi Nango; Hiroki Kasai; Takuya Yanagi; Takayuki Mawatari; Kenta Nishiyama; Hiroko Miyagishi; Kumiko Ishige; Yoshihisa Ito
Journal:  Oxid Med Cell Longev       Date:  2020-01-11       Impact factor: 6.543

5.  Bidens pilosa Extract Administered after Symptom Onset Attenuates Glial Activation, Improves Motor Performance, and Prolongs Survival in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Yasuhiro Kosuge; Erina Kaneko; Hiroshi Nango; Hiroko Miyagishi; Kumiko Ishige; Yoshihisa Ito
Journal:  Oxid Med Cell Longev       Date:  2020-01-29       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.